# Subject Index


A

Adenocarcinoma
  vaginal
    due to maternal oestrogen 7: 469–470
β-adrenergic receptor blocking drugs
  adverse reactions
    airways obstruction 7: 456
    atrioventricular conduction delay 7: 455–456
    heart failure 7: 455
    immunological complications 7: 457
    sinus arrest 7: 456
  arrhythmias 7: 426–462
  DC cardioversion 7: 446–447
  electrophysiological effect 7: 430–433
    on pacemaker potentials 7: 430
    on membrane-depressant effect 7: 431–432
  myocardial infarction 7: 442–446
  pacemakers, artificial 7: 449
Alprenolol
  arrhythmias 7: 425–453
Amitriptyline poisoning
  in children 7: 470–471
Arrhythmias
  β-adrenergic receptor blocking
    drugs 7: 433–442
  alprenolol 7: 452–453
  electrophysiology 7: 429–430
  oxprenolol 7: 453
  pindolol 7: 453–454
  practolol 7: 454–455
  propranolol 7: 451–452
Arrhythmias; after cardiac surgery
  β-adrenergic receptor blocking
    drugs 7: 447–448
Arrhythmias: digitalis-induced
  β-adrenergic receptor blocking
    drugs 7: 449–450
Arrhythmias, intrasurgical
  β-adrenergic receptor blocking
    drugs 7: 448
Arrhythmias, supraventricular
  β-adrenergic receptor blocking
    drugs 7: 433–438
Arrhythmias, ventricular
  β-adrenergic receptor blocking
    drugs 7: 438–442

B

Beclomethasone
  in hay fever 7: 478–479
Bioavailability
  digoxin 7: 467–468, 468–469
  tetracycline 7: 465–466

# Subject Index


A

Adenocarcinoma
  vaginal
    due to maternal oestrogen 7: 469–470
β-adrenergic receptor blocking drugs
  adverse reactions
    airways obstruction 7: 456
    atrioventricular conduction delay 7: 455–456
    heart failure 7: 455
    immunological complications 7: 457
    sinus arrest 7: 456
  arrhythmias 7: 426–462
  DC cardioversion 7: 446–447
  electrophysiological effect 7: 430–433
    on pacemaker potentials 7: 430
    on membrane-depressant effect 7: 431–432
  myocardial infarction 7: 442–446
  pacemakers, artificial 7: 449
Alprenolol
  arrhythmias 7: 425–453
Amitriptyline poisoning
  in children 7: 470–471
Arrhythmias
  β-adrenergic receptor blocking
    drugs 7: 433–442
  alprenolol 7: 452–453
  electrophysiology 7: 429–430
  oxprenolol 7: 453
  pindolol 7: 453–454
  practolol 7: 454–455
  propranolol 7: 451–452
Arrhythmias; after cardiac surgery
  β-adrenergic receptor blocking
    drugs 7: 447–448
Arrhythmias: digitalis-induced
  β-adrenergic receptor blocking
    drugs 7: 449–450
Arrhythmias, intrasurgical
  β-adrenergic receptor blocking
    drugs 7: 448
Arrhythmias, supraventricular
  β-adrenergic receptor blocking
    drugs 7: 433–438
Arrhythmias, ventricular
  β-adrenergic receptor blocking
    drugs 7: 438–442

B

Beclomethasone
  in hay fever 7: 478–479
Bioavailability
  digoxin 7: 467–468, 468–469
  tetracycline 7: 465–466

C

Cardiac abnormality
risks in dental treatment 7: 479–480
Cardiac arrhythmias see
arrhythmias
DC-Cardioversion
β-adrenergic receptor blocking
drugs 7: 446–447
Chorea
tetrabenazine 7: 477–478
Colitis, ulcerative
Salicylazosulphapyridine metabolism 7: 463–464

D

Dental treatment
in cardiac abnormality 7: 479–480
Diethylstilboestrol
adverse reactions 7: 469–470
Digitalis glycosides
pharmacokinetics 7: 482–485
Digoxin
bioavailability tests 7: 467–468, 468–469
Diuretics
mefruside 7: 419–425
Drug advertising 7: 412–413, 417–418
Drug control 7: 412–413
Drug labels 7: 414–418
and advertising 7: 417–418
contents 7: 415–417
primary function 7: 414–415
Drug marketing
advertising 7: 412–413
control 7: 412–413
drug testing
in animals 7: 409–410
in man 7: 410–412
legislation 7: 409
patient information 7: 413
Drug product information 7: 414–418
Drug reactions, adverse
β-adrenergic receptor blocking
drugs 7: 455–457
diethylstilboestrol 7: 469–470
mefruside 7: 424–425
oestrogen 7: 469–470
pheniramine 7: 471–472
Salicylazosulphapyridine 7: 462–463
Drug trials 7: 409–412
in animals 7: 409–410
in man 7: 410–411
mefruside 7: 422–424

E

Ectopics, supraventricular
β-adrenergic receptor blocking
drugs 7: 433–434
Ectopics, ventricular
β-adrenergic receptor blocking
drugs 7: 438–439

F

Fibrillation, atrial
β-adrenergic receptor blocking
drugs 7: 436–437
Fibrillation, ventricular
β-adrenergic receptor blocking
drugs 7: 440–442
Flutter, atrial
β-adrenergic receptor blocking
drugs 7: 437–438
Frusemide
in acute renal failure 7: 475–476

H

Hay fever
beclomethasone, intranasal 7: 478–479

I

Impramine
withdrawal symptoms 7: 473
Imipramine poisoning
in children 7: 470–471
Isoniazid
dosage in renal failure 7: 466–467

L

Levodopa
Parkinson's disease 7: 474–475

M

Mefruside
dosage 7: 425
pharmacology 7: 420–422
diuretic effect 7: 420
hypotensive effect 7: 421
metabolic effects 7: 421–422
site of action 7: 420–421
side effects 7: 424–425
therapeutic efficacy 7: 422–424
oedema 7: 422–423
hypertension 7: 423–424
Myocardial infarction
β-adrenergic receptor blocking
drugs 7: 442–446

effect of catecholamines 7: 442
prophylactic use 7: 443
therapeutic use 7: 443–445
therapeutic regimen 7: 445

O

Oestrogen
adverse reactions 7: 469–470
Oxprenolol
arrhythmias 7: 453

P

Parkinson's disease
Levodopa 7: 474–475
Pheniramine
hallucinations with 7: 471–472
Pindolol
arrhythmias 7: 453–454
Practolol
arrhythmias 7: 454–455
Propranolol
arrhythmias 7: 451–452
Pustulosis palmaris et plantaris
tetracycline 7: 476–477

Q

Quinidine
DC cardioversion 7: 446–447

R

Renal failure
high dose frusemide 7: 475–476
isoniazid dosage 7: 466–467

S

Salicylazosulphapyridine
adverse reactions 7: 462–463
metabolism 7: 463–464
in health 7: 463–464
in ulcerative colitis 7: 463–464

T

Tachycardia, sinus
β-adrenergic receptor blocking drugs 7: 433
Tachycardia, supraventricular
β-adrenergic receptor blocking drugs 7: 434–436
Tachycardia, ventricular
β-adrenergic receptor blocking drugs 7: 440–442
Tetrabenazine
in chorea 7: 477–478
Tetracycline
bioavailability 7: 465–466
pustulosis palmaris et plantaris 7: 476–477
Tuberculosis, pulmonary
treatment 7: 481

Vol. 7, 1974

# Drugs

International Journal of Current Therapeutics and Applied Pharmacology Reviews, featuring Evaluations on New Drugs, Review Articles on Drugs and Drug Therapy, and Drug Literature Abstracts


*Editor* — *G.S. Avery*

*Associate Editors* — *R.N. Brogden*, *D.N. McDonald*, *Rosalind Spencer*, *T.M. Speight*

*Assistant Editor* — *I.W. Davey*

*Chief Consulting Editor* — *G.S. McL. Kellaway*

*Consulting Editors*

*T.F. Acheson*, Sydney
*J.W. Ardagh*, Christchurch
*R.R. Bailey*, Christchurch
*J.A. Baird*, Wellington
*Sir Brian Barratt-Boyes*, Auckland
*R.W. Beal*, Adelaide
*D.W. Beaven*, Christchurch
*R.F.A. Becke*, Sydney
*D.G. Bonham*, Auckland
*J.S. Boyd-Wilson*, Wellington
*E.P. Brasted*, Auckland
*D.A. Bremner*, Auckland
*J.G. Buchanan*, Auckland
*Patricia Buckfield*, Dunedin
*R. Carruthers*, Launceston
*D.S. Cole*, Auckland
*W.H.J. Cole*, Melbourne
*J.F. Copplestone*, Geneva
*J.M. Court*, Melbourne
*L.W. Cox*, Adelaide
*Marion D. Cridland*, Sydney
*J.A.K. Cuningham*, Christchurch
*M.H.L. de Groot*, Toowoomba
*I.S. de la Lande*, Adelaide
*P.B. Doak*, Auckland
*A.E. Doyle*, Melbourne
*M.J. Eadie*, Brisbane
*Keitha Farmer*, Auckland
*D.W. Feeney*, Auckland
*T. Gebbie*, Wellington
*G.H. Green*, Auckland
*D.R. Hay*, Christchurch
*P.B. Herdson*, Auckland
*G.C. Hitchcock*, Auckland
*F.C. Hollows*, Sydney
*C. McK. Holmes*, Dunedin
*W.R. Holmes*, Christchurch
*R.N. Howie*, Auckland
*H.K. Ibbertson*, Auckland
*L.B. Jellet*, Perth
*Priscilla Kincaid-Smith*, Melbourne
*J.W. Lance*, Sydney
*J.H. Lee*, Sydney
*Sir William Liley*, Auckland
*P.J. Little*, Christchurch
*W.J. Louis*, Victoria
*A.D. Macalister*, Dunedin
*J.B. Mackay*, Wellington
*E.G. McQueen*, Dunedin
*D.S. Malcom*, Dunedin
*G. Milner*, Melbourne
*O.R. Nicholson*, Auckland
*J.D.K. North*, Auckland
*K.P. O'Brien*, Auckland
*R.G. Park*, Wellington
*D.W. Piper*, Sydney
*W.M. Platts*, Christchurch
*D.E. Poswillo*, London
*L.W. Powell*, Brisbane
*M.J. Purdy*, Hamilton
*M.J. Rand*, Melbourne
*P.C. Reade*, Melbourne
*R.G. Robinson*, Sydney
*B.S. Rose*, Hamilton
*W.S. Rose*, Brisbane
*N. Roydhouse*, Auckland
*M.J.W. Sando*, Adelaide
*R.J. Seddon*, Auckland
*F.O. Simpson*, Dunedin
*B.N. Singh*, Auckland
*J.G. Sloman*, Melbourne
*B.C. Stratford*, Melbourne
*P. Taft*, Melbourne
*C. Tasman Jones*, Auckland
*J. Tonkin*, Sydney
*J.H. Tyrer*, Brisbane
*A.M.O. Veale*, Dunedin
*D.N. Wade*, Sydney
*J.M. Watt*, Dunedin
*F.A. Whitlock*, Brisbane
*R. Zacest*, Woodville


adis

Australasian Drug Information Services Pty. Ltd. Sydney

Australasian Drug Information Services Pty. Ltd., P.O. Box 194,
Balgowlah/Sydney, NSW 2093 (Australia)

---

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including pl otocopying or recording or by any information storage and retrieval system, without permission in writing from the publishers.

© Copyright 1974 by Australasian Drug Information Services Pty. Limited, Sydney
Printed in Switzerland by Thür AG Offsetdruck, Pratteln

## Contents


*Guest Editorials*

*Godfrey, R.C. and Howell, J.B.L.* (England): Sodium Cromoglycate: A Clinical View . . . . . 161–163

*Harrison, D.C.* (Stanford): The Pharmacology and Therapeutic Use of β-Adrenergic Receptor Blocking Drugs in Cardiovascular Disease . . . . 1–7

*Turtle, J.R.* (Sydney): New Concepts in Adipose Tissue Metabolism and Obesity 321–322

*Vohra, J.K.* (Melbourne): Cardiovascular Abnormalities following Tricyclic Antidepressant Drug Overdose . . . . . 323–325

*Special Articles*

*Hollister, L.E.* (California): Drug Product Information: Sensible Disclosure of Clinically Important Facts . . . . . 414–418

*Lasagna, L.* (New York): Minimum Acceptable Requirements for Introduction and Marketing of Drugs . . . . . 409–413

*Evaluations on New Drugs*

*Brogden, R.N.; Speight, T.M. and Avery, G.S.* (Auckland): Sodium Cromoglycate (Cromolyn Sodium): A Review of its Mode of Action, Pharmacology, Therapeutic Efficacy and Use

Part I: Asthma . . . . . 164–282

Part II: Allergic Rhinitis and Other Conditions . . . . . 283–296

*Brogden, R.N.; Speight, T.M. and Avery, G.S.* (Auckland): Amoxycillin: A Preliminary Report of its Pharmacokinetic Properties and Therapeutic Efficacy . . . . . 326–336

*Brogden, R.N.; Speight, T.M. and Avery, G.S.* (Auckland): Fluocinonide in FAPG Base: A Review of its Therapeutic Efficacy in Inflammatory Dermatoses . . . . . 337–343

*Brogden, R.N.; Speight, T.M. and Avery, G.S.* (Auckland): Mefruside: A Preliminary Report of its Pharmacological Properties and Therapeutic Efficacy in Oedema and Hypertension . . . . . 419–425

*Review Articles*

*Beumer, H.M.* (Utrecht): Adverse Effects of β-Adrenergic Blocking Drugs on Respiratory Function . . . . . 130–138

*Furberg, C.D.* (Boden): β-Adrenergic Receptor Blocking Drugs in Hypertrophic Obstructive Cardiomyopathies, Certain Functional Heart Disorders and Fallot's Tetralogy . . . . . 106–117

*Gibson, D.G.* (London): Pharmacodynamic Properties of Adrenergic Receptor Blocking Drugs in Man . . . . . 8–38

*Greenblatt, D.J. and Koch-Weser, J.* (Boston): Adverse Reactions to Adrenergic Receptor Blocking Drugs: A Report from the Boston Collaborative Drug Surveillance Program . . . . . 118–129
*Prichard, B.N.C.* (London): β-Adrenergic Receptor Blocking Drugs in Angina Pectoris . . . . . 55–84
*Rebuck, A.S.* (Ontario): Antiasthmatic Drugs I: Pathophysiological and Clinical Pharmacological Aspects . . . . . 344–369
*Rebuck, A.S.* (Ontario): Antiasthmatic Drugs II: Therapeutic Aspects . . . . . 370–390
*Shand, D.G.* (Nashville): Pharmacokinetic Properties of β-Adrenergic Receptor Blocking Drugs . . . . . 39–47
*Simpson, F.O.* (Dunedin): β-Adrenergic Receptor Blocking Drugs in Hypertension 85–105
*Singh, B.N.* (Auckland) *and Jewitt, D.E.* (London): β-Adrenergic Receptor Blocking Drugs in Cardiac Arrhythmias . . . . . 426–461
*Turner, P.* (London): β-Adrenergic Receptor Blocking Drus in Hyperthyroidism 48–54

*Practical Therapeutics*
*Bauer, G.E.* (Sydney): Treatment of Hypertension in the Elderly . . . . . 310–318
*Roydhouse, N.* (Auckland): Vertigo and its Treatment . . . . . 297–309

*Drug Literature Abstracts* . . . . . 139, 391, 462

*Correspondence* . . . . . 482

*Subject Indices* . . . . . 157, 319, 406, 486

**Progress in Biochemical Pharmacology, Vol. 8**

Series Editor:
*R. Paoletti* (Milan)

# Effect of Carbohydrates on Lipid Metabolism

**Effect of Carbohydrates on Lipid Metabolism**
Volume Editor:
*I. Macdonald* (London)
X + 314 p., 24 fig., 38 tab., 1973
SFr. 144.– / US $ 52.50 /
DM 136.80 / £ 20.90
ISBN 3–8055–1600–2

*Heinz, F.* (Hannover-Kleefeld): The Enzymes of Carbohydrate Degradation
*Kupke, I.R.* (Hannover-Kleefeld): Lipid Biosynthesis
*Nestel, P.J.* (Canberra): Triglyceride Turnover in Man. Effects of Dietary Carbohydrate
*Zakim, D.* (San Francisco, Calif.): Influence of Fructose on Hepatic Synthesis of Lipids
*Vrána, A. and Fabry, P.* (Prague): Dietary Carbohydrates and Adipose Tissue Metabolism
*Macdonald, I.* (London): Effects of Dietary Cabohydrates on Serum Lipids
*Albrink, Margaret J.* (Morgantown, W.Va.): Dietary Carbohydrates in Lipid Disorders in Man
*Nikkilä, E.A.* (Helsinki): Triglyceride Metabolism in Diabetes mellitus

This volume consists of contributions concerned with various aspects of carbohydrate lipid interrelationships. The areas covered include: an account of the enzymes involved in this interrelationship; triglyceride turnover in response to dietary carbohydrate; dietary fructose and hepatic lipid synthesis; dietary carbohydrates and adipose tissue metabolism; the effects of dietary carbohydrates on serum lipids and in human lipid disorders; the triglyceride metabolism in diabetes and the influence of drugs on the carbohydrate lipid relationship. The volume will provide those knowledgeable in one part of this important metabolic field an up-to-date review of the state of knowledge in related areas.

S. Karger
Basel · München · Paris · London
New York · Sydney

KI 73041

## General Information

*Publication data:* Two volumes of *Drugs* are published annually. Each volume comprises six 80-page issues. Subscription price per volume SFr. 135. – / US $49.00 / DM128. – / £19.60 including postage. Multiple subscription rates on request. *Drugs* is published by Australasian Drug Information Services Pty. Ltd., 559 Sydney Road, Seaforth, N.S.W. Australia.

*Subject index:* Each issue has its own comprehensive subject index which is cumulated in issue No. 6 of the second volume in each year.

*Editorial matter* is prepared by our own professionally qualified editorial staff and by honorary specialist consultants from all fields of medicine. While great care has been taken in compiling and checking the information contained in *Drugs*, the publisher cannot accept any responsibility for errors or omissions. The inclusion or exclusion of any product does not mean that the publisher advocates or rejects its use either generally or in any particular field or fields.

*Drug nomenclature:* Approved names of the British Pharmacopoeia Commission are used throughout the text. When the Commission has not adopted a name for the drug under discussion, the United States Adopted Name (USAN – United States Pharmacopeial Convention Inc) or the International Non-Proprietary Name (INN – WHO) is used. When available, all three names are given at the head of the evaluations on new drugs and review article sections, and elsewhere in the text as appropriate. Other synonyms (e.g. research code names of new drugs) are also given.

*Correspondence:* Letters to the editor are welcomed. They should be submitted in duplicate typewritten on one side of the paper only and double-spaced with a wide margin. They should be of reasonable length and written in English. Letters will be published if found suitable and will be subject to editorial review and possible abridgement.

*Manuscripts:* Information on the preparation of manuscripts will be provided to authors.

*Copyright* © 1974 Australasian Drug Information Services Pty Limited. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying or recording or by any information storage and retrieval system, without permission in writing from the publishers.

## Subscription

*Subscription orders* can be placed with any bookstore or direct with the distributors S. Karger AG, Arnold-Böcklin-Strasse 25, CH–4011 Basel (Switzerland), or else with the following:

### Subscription Order Form

Please enter my subscription for Drugs beginning with

☐ Vol. 1, 1971 ☐ Vol. 4, 1972 ☐ Vol. 7, 1974
☐ Vol. 2, 1971 ☐ Vol. 5, 1973 ☐ Vol. 8, 1974
☐ Vol. 3, 1972 ☐ Vol. 6, 1973

Name _____

Title _____

Address _____

_____

City _____

State/Zip _____

*Bundesrepublik Deutschland:* S. Karger GmbH, Postfach 2, D–8034 Germering/München
*France:* S. Karger S.A., 42bis, Bd de La Tour-Maubourg, F–75 Paris 7e
*Great Britain:* John Wiley and Sons Ltd., Baffins Lane, Chichester, Sussex
*USA:* Albert J. Phiebig Inc., US Representative of S. Karger, P.O. Box 352, White Plains, NY 10602
*Australia:* Australasian Drug Information Services Pty.Ltd., Agents in Australasia for S. Karger, P.O. Box 194, Balgowlah/Sydney, NSW 2093
*New Zealand:* Australasian Drug Information Services Pty.Ltd., New Zealand Office, P.O. Box 30–049, Takapuna North/Auckland 9